AKANDA CORP. AKAN

Healthcare SIC 2833 - Medicinal Chemicals & Botanical Products NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Medicinal and Botanical Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue —$836.7K$423.7K$2.6M$41.4K$2.1K——
Operating income —-$4.4M-$3.7M-$20.2M-$2.6M-$1.7M-$901.2K—
Net income —-$4.1M-$32.3M-$11.7M-$8.1M-$2.3M-$1.4M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets —$7.9M$8.8M$39.0M$8.0M$4.3M——
Total equity —$4.3M-$3.8M$26.9M-$2.2M-$5.0M-$2.9M-$1.5M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-066800.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -40M -30M -20M -10M 0 10M Net income, FY2019: -1.4M Revenue, FY2020: 2.1K Net income, FY2020: -2.3M Revenue, FY2021: 41.4K Net income, FY2021: -8.1M Revenue, FY2022: 2.6M Net income, FY2022: -11.7M Revenue, FY2023: 423.7K Net income, FY2023: -32.3M Revenue, FY2024: 836.7K Net income, FY2024: -4.1M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — $2.1K $41.4K $2.6M $423.7K $836.7K —
Gross profit — — — — — — — —
Net income — -$1.4M -$2.3M -$8.1M -$11.7M -$32.3M -$4.1M —

Others in SIC 2833

TickerCompanyMarket capP/ERevenue growth
DFTX Definium Therapeutics, Inc. $5.12B — —
TRLV Trulieve Cannabis Corp. $2.33B — -0.4%
CRON Cronos Group Inc. $1.20B — 24.6%
TLRY Tilray Brands, Inc. $612.9M — 11.5%
CGC Canopy Growth Corp $411.5M — —
USNA USANA HEALTH SCIENCES INC $276.4M 25.8x 8.3%
NAGE Niagen Bioscience, Inc. $250.8M 15.8x 29.9%
FTLF FITLIFE BRANDS, INC. $92.2M 15.6x 26.4%